Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Interest Expenses (2022 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Interest Expenses for 4 consecutive years, with $22.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest Expenses rose 3.97% year-over-year to $22.5 million, compared with a TTM value of $90.2 million through Dec 2025, up 85.52%, and an annual FY2025 reading of $89.4 million, up 176.21% over the prior year.
  • Interest Expenses was $22.5 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $21.7 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $24.4 million in Q2 2025 and bottomed at $2.8 million in Q4 2022.
  • Average Interest Expenses over 4 years is $12.5 million, with a median of $7.2 million recorded in 2024.
  • The sharpest move saw Interest Expenses decreased 1.24% in 2024, then soared 378.64% in 2025.
  • Year by year, Interest Expenses stood at $2.8 million in 2022, then skyrocketed by 88.38% to $5.4 million in 2023, then soared by 303.32% to $21.6 million in 2024, then increased by 3.97% to $22.5 million in 2025.
  • Business Quant data shows Interest Expenses for ARWR at $22.5 million in Q4 2025, $21.7 million in Q3 2025, and $24.4 million in Q2 2025.